Valuation: Simulations Plus

Market Cap 37Cr 33Cr 31Cr 28Cr 53Cr 3.62TCr 54Cr 374.23Cr 146.37Cr 1.84TCr 140.48Cr 137.43Cr 5.92TCr P/E 2026 *
46.3x
P/E 2027 * 42x
Enterprise Value 37Cr 33Cr 31Cr 28Cr 53Cr 3.62TCr 54Cr 374.23Cr 146.37Cr 1.84TCr 140.48Cr 137.43Cr 5.92TCr EV / Sales 2026 *
4.57x
EV / Sales 2027 * 4.36x
Free-Float
99.98%
Yield 2026 *
-
Yield 2027 * -
1 week+0.05%
Current month+0.38%
1 month+0.43%
3 months+1.26%
6 months+42.31%
Current year+1.48%
1 week 18.49
Extreme 18.49
18.5
1 month 18.4
Extreme 18.4
18.5
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.1
Extreme 8.1011
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Issuer sale

Chairman

-23,547 0.1169%
06/10/26 Issuer sale

Chief Financial Officer

-1,09,600 0.5440%
06/10/26 Issuer sale

Founder

-32,07,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.05%+12.33%-57.65% 37Cr
-1.52%-0.08%+21.59%+30.78% 24TCr
-0.47%+2.69%+6.10%+0.11% 15TCr
+0.21%+3.53%-7.29%+40.49% 15TCr
+1.11%-2.75%-56.57%-19.34% 6.09TCr
-1.80%-1.12%+11.22%+14.30% 4.86TCr
+1.42%+2.54%-19.94%-17.37% 4.77TCr
-0.54%+0.89%+19.43%+52.00% 4.74TCr
+0.83%+1.03%-5.62%+35.90% 4.61TCr
-1.57%+0.85%+30.97%+60.48% 4.22TCr
Average -0.23%+0.34%+1.22%+13.97% 8.34TCr
Weighted average by Cap. -0.50%+0.46%+3.82%+22.44%

Financials

2026 *2027 *
Net sales 8.18Cr 7.3Cr 6.81Cr 6.19Cr 12Cr 792.2Cr 12Cr 82Cr 32Cr 402.56Cr 31Cr 30Cr 1.29TCr 8.58Cr 7.66Cr 7.14Cr 6.49Cr 12Cr 830.56Cr 12Cr 86Cr 34Cr 422.05Cr 32Cr 31Cr 1.36TCr
Net income 76.35L 68.18L 63.6L 57.78L 1.09Cr 74Cr 1.1Cr 7.64Cr 2.99Cr 38Cr 2.87Cr 2.8Cr 120.84Cr 89.97L 80.34L 74.95L 68.08L 1.28Cr 87Cr 1.29Cr 9Cr 3.52Cr 44Cr 3.38Cr 3.3Cr 142.4Cr
Net Debt - -
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
05/26/05 $18.50 0.00% 6,25,309
02/26/02 $18.50 +0.05% 4,60,260
01/26/01 $18.49 +0.33% 8,65,859
30/26/30 $18.43 -0.27% 3,32,435
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Simulations Plus